Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | HINT1 | P49773 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401856 | 0.92 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1HPGDTAAR1 | |
| SCHEMBL18520965 | 0.89 | TAS1R3 (0.59) | KDM4ETAS1R3TAS1R1HPGDHINT1 | |
| SCHEMBL25387607 | 0.89 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1HPGDTAAR1 | |
| SCHEMBL24377105 | 0.89 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1HPGDTAAR1 | |
| SCHEMBL24377219 | 0.89 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1HPGDTAAR1 | |
| SCHEMBL25389665 | 0.89 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1HPGDTAAR1 | |
| SCHEMBL29973219 | 0.89 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1HPGDTAAR1 | |
| SCHEMBL20210330 | 0.87 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDHINT1 | |
| SCHEMBL21878146 | 0.87 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDHINT1 | |
| SCHEMBL22883375 | 0.87 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| CN-118873678-A | Antibody-conjugated drugs and uses thereof | 泰励生物科技（上海）有限公司 | 2024-11-01 | — | — | CN | disclosed |
| WO-2024153127-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20240059729-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-02-22 | — | — | US | disclosed |
| CN-117015383-A | Multifunctional cyclic dinucleotide and application thereof | 泰励生物科技（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-4242218-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| CN-115160392-A | Multifunctional cyclic dinucleotide and application thereof | 泰励生物科技（上海）有限公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022083584-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059729-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | MAVS, IRF3, STING1 | KDM4E 2917/4885TAS1R3 4161/4885TAS1R1 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.